Silence Therapeutics

SLN

Market cap $238M

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has served as the Company's President, Chief Executive Officer and Board member since 2022, agreed by mutual consent to end his employment with the Company effective 14 December 2025. Iain Ross, Chairman of the Silence Board, will lead the Company with immediate effect on an i.

Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 8:00 a.m. ET (1:00 p.m. GMT). The live webcast can be accessed in the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2025, and reviewed recent business highlights. “Silence continues to focus on operational execution, highlighted by the rapid achievement of full enrollment in our ongoing SANRECO Phase 2 study of divesiran, our first-in-class siRNA for.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced it has completed patient enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6, for the treatment of polycythemia vera (PV). Initial topline results from the SANRECO Phase 2 study are anticipated in the third quarter of 2026. SANRECO is a global, randomized, double-blind, placebo-contro.

Silence Therapeutics plc (NASDAQ:SLN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Michael Ulz - Equity Analyst Craig Tooman - President, CEO & Executive Director Steven Romano - Executive VP and Chief Research & Development Officer Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in the following conferences: Morgan Stanley Global Healthcare Conference Fireside Chat on Tuesday, September 9, 2025 at 5:35 p.m. ET H.C. Wainwright Global Investment Conference Fireside Chat on Wednesday, September 10, 2025 at 12:00 p.m. ET The webcasts can be acce.

Silence Therapeutics Plc (SLN -1.32%), a biotechnology company focused on developing RNA interference (RNAi) therapeutics, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $224 thousand, far below analyst estimates, while net loss widened year over year to $27.4 million from $19.8 million.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the second quarter ended June 30, 2025, and reviewed recent business highlights. “The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV,” said Craig Tooman, Pres.

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia vera (PV) at the European Hematology Association (EHA) 2025 Annual Meeting in Milan, Italy. “The latest data presented at EHA today continue to demonstrate divesiran's potential to maintain rapid and dur.